Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

39.11
+0.57001.48%
Post-market: 39.00-0.1100-0.28%19:40 EDT
Volume:1.80M
Turnover:69.69M
Market Cap:3.35B
PE:-9.01
High:39.35
Open:38.73
Low:38.25
Close:38.54
Loading ...

The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex

Zacks
·
06 Feb

Cathie Wood-Led Ark Invest Continues to Sell Palantir Shares As Rally Cools Down

Benzinga
·
06 Feb

Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today

Zacks
·
05 Feb

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Feb

Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?

Zacks
·
03 Feb

HC Wainwright Initiates CRISPR Therapeutics at Buy With $65 Price Target

MT Newswires Live
·
03 Feb

Crispr Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
03 Feb

CRISPR Therapeutics Ag : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $65

THOMSON REUTERS
·
03 Feb

Crispr Therapeutics initiated with a Buy at H.C. Wainwright

TIPRANKS
·
03 Feb

Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker

Blockhead
·
31 Jan

Vertex Pharmaceuticals announces Casgevy reimbursement pact with NHS England

TIPRANKS
·
31 Jan

Vertex Pharmaceuticals Sickle Cell Therapy to be Reimbursed by England's National Health Service

MT Newswires Live
·
31 Jan

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

Business Wire
·
31 Jan

Jim Cramer Says “CRISPR (CRSP) Keeps Losing Money Like Moderna” – Here’s Why

Insider Monkey
·
31 Jan

CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors

Zacks
·
30 Jan

CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

GlobeNewswire
·
29 Jan

Maravai Lifesciences Acquires Molecular Assemblies' Intellectual Property, Related Assets

MT Newswires Live
·
29 Jan

Modalis Therapeutics Secures Japanese Patent for Gene Therapy

MT Newswires Live
·
27 Jan

Crispr Therapeutics price target lowered to $30 from $45 at Morgan Stanley

TIPRANKS
·
27 Jan

Morgan Stanley Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)

TIPRANKS
·
27 Jan